Characteristics | Lapatinib + paclitaxel (n = 222) | Placebo + paclitaxel (n = 222) |
---|---|---|
Patients with available tumor tissue, n (%) | 198 (89) | 192 (86) |
Tumors available for PTEN a , n (%) | 180 | 175 |
  PTEN IHC 0 | 28 (16) | 21 (12) |
  PTEN IHC 1+ | 76 (42) | 80 (46) |
  PTEN IHC 0/1+ | 104 (58) | 101 (58) |
  PTEN IHC 2+/3+ | 76 (42) | 74 (42) |
Patients consented for PIK3CA b | 141 | 133 |
Tumors evaluable for PIK3CA a , n (%) | 104 | 106 |
  PIK3CA mutation | 29 (28) | 36 (34) |
  PIK3CA wild-type | 58 (56) | 48 (45) |
  PIK3CA indeterminate | 17 (16) | 22 (21) |
Tumors with PTEN IHC 0/1+ and/or PIK3CA mutations c,d , n (%) | 119/180 (66) | 117/175 (67) |
Tumors with PTEN IHC 0/1+ and PIK3CA mutation, n (%) | 14/104 (13) | 20/106 (19) |